β-hCG on the day of retrieval. Zegers-Hochschild et al. (5) , showed absent serum β-hCG 12 h after IM injection in EFS cycles compared to a mean of 207.5 mIU/mL in controls. Both hCG batches had similar biological activity on rat Leydig cell preparations. However, when 5,000 IU hCG were injected intravenously into male volunteers, the EFS batches showed no detectable levels 10 min later. Injections from control batches resulted in serum levels of nearly 3,000 mIU/mL at 10 min. The authors concluded that EFS may result from rapid plasma clearance of hCG because of the high affinity of liver cells for certain abnormal batches. Ndukwe et al. (3) , showed that serum β-hCG levels ranged from 106 to 290 mIU/mL (mean 209) 36 h after hCG injection in women with successful oocyte retrieval. This compares to a range of 0 to 9 mIU/mL (mean 4) in EFS patients. They suggested that retrievals be interrupted, and a β-hCG level checked if no oocytes are recovered from all follicles on one ovary. This leaves the other ovary intact for a successful retrieval after a second injection of hCG. In the two cases we report, we were unable to recover any oocytes from the follicles that had been previously punctured despite repeated flushing while the yield from intact follicles was excellent. Our experience suggests that when the first few follicles fail to yield oocytes, a urine pregnancy test should be promptly performed and the retrieval discontinued while awaiting confirmation of suboptimal levels on a blood test. This avoids aspiration and vigorous repeated flushing of all follicles in a desperate attempt to recover an egg when the absence of hCG has prevented the loosening of the oocyte-cumulus complex from the follicle wall.
Occasionally, as reported by Hassan et al. (6) and Awonuga et al. (2) , eggs are not recovered despite the presence of adequate serum β-hCG levels (range 145-377). In these reports, a successful oocyte retrieval was achieved 24 h later, after a second hCG injection. Assuming that the patients described in these studies had taken their hCG injection 35 h prior to the first retrieval (as opposed to the night before retrieval), we believe that these instances represent unusual exceptions. As a general rule, finding no eggs in the initial few follicles does not warrant interrupting the retrieval as long as satisfactory levels of β-hCG are present. This will avoid premature discontinuation of procedures where, for no obvious reason, no oocytes are found in the first few follicles, yet an adequate number of oocytes is obtained from the subsequent follicles. 
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INTRODUCTION
Gonadotropin-releasing hormone (GnRH) agonists are routinely used in in vitro fertilisation (IVF) treatment to prevent premature luteinisation. The incidence of cycle cancellation due to premature luteinisation is approximately 2%. Well documented adverse side effects of treatment include symptoms of estrogen deprivation and the formation of ovarian cysts. Ovarian cyst formation after GnRH agonist administration has been reported in 10-29% of IVF cycles (1-2).
In a small proportion of women, paradoxical ovarian stimulation occurs which results in multifollicular ovarian enlargement and markedly elevated estradiol levels. This is a rare event and a literature search has revealed a small number of reported cases (3) (4) (5) . The management has differed between cases, but no cycle resulting in pregnancy has been reported.
We present here the first reported case, to our knowledge, where the sole administration of Nafarelin spray, commenced in the luteal phase in a normally cycling woman, led to the development of ovarian hyperstimulation.
CASE REPORT
A 33-year-old female presented for her first IVF cycle. She had a 32 month history of primary infertility. Diagnostic evaluation revealed variable ovulation and bilateral tubal patency. There was no ultrasonographic or biochemical (FSH 5.2 U/L; LH 4.7 U/L) evidence of polycystic ovarian syndrome. Her husband had a right orchidectomy as a teenager secondary to testicular torsion. As a result of recurrent urethral stricture formation, a two-stage urethroplasty had been performed. This may have given rise to an ejaculatory disorder with pooling of semen in the distal urethra. Except for a low ejaculatory volume, semen analysis was within normal limits. Nine cycles of treatment with clomiphene citrate and artificial insemination, using her husband's sperm were unsuccessful. The couple were then referred for IVF treatment. Baseline investigations prior to treatment included a normal pelvic ultrasound and hormonal profile (
Nafarelin spray 400 µg intranasally twice daily was commenced on day 25 of a spontaneous menstrual cycle. After 14 days of Nafarelin administration, she was evaluated for pituitary desensitisation. At this time she complained of abdominal bloating, breast tenderness, and mild nausea. Transvaginal ultrasound scan revealed nine follicles in both ovaries, ranging from 13 to 30 mm diameter. The maximum ovarian dimension was 6 cm. Endometrial thickness measured 5 mm. There was no evidence of ascites. Laboratory investigations revealed the following results: serum oestradiol = 10,362 pmol/L, progesterone = 6.5 nmol/L, FSH < 1.0 U/L, LH = 4.2 U/L, and hCG < 5 U/L. A diagnosis of ovarian hyperstimulation was made. The patient was advised to continue Nafarelin spray to maintain suppression of pituitaryovarian function.
The patient was reviewed the following day. Investigations revealed the following: serum estradiol = 7735 pmol/L, progesterone = 5.3 nmol/L, FSH < 1.0 U/L, and LH = 3.0 U/L. She was asked to report any increase in symptoms and to attend for review 1 week later. At review, she admitted discontinuing Nafarelin spray 4 days earlier. Transvaginal scan showed eight follicles ranging from 7.5 to 30 mm diameter. Ovarian dimensions remained unchanged. Symptomatically she was much improved. Hormonal profile revealed a significant decrease in serum estradiol to 164 pmol/L, progesterone = 1.7 nmol/L, FSH = 3.4 U/L, and LH = 1.9 U/L. Ultrasonography 6 weeks later revealed ovaries of normal size and appearance.
At her follow-up appointment she wished to pursue further treatment. However, she was concerned about the risk of recurrence of hyperstimulation and cycle cancellation. After discussion the patient opted for a cycle, using the GnRH antagonist Cetrorelix (ASTA Medica). The protocol used was similar to the regime described by Albano et al. (6) . Treatment with 150 IU Menogon (Ferring) was commenced on day 2 of the menstrual cycle. Cetrorelix 3 mg was administered subcutaneously on the sixth day of ovarian stimulation. A further dose of 0.25 mg was administered 4 days later. Ultrasound on day 10 of stimulation revealed 12 follicles greater than 14 mm in diameter. The maximum ovarian dimension was 5.2 cm. Laboratory investigations on day 10 of stimulation were as follows: serum estradiol = 4012 pmol/L, LH = 7.2 U/L. Profasi 5,000 IU (Serono) was administered and oocyte retrieval was performed 36 h later. Eight oocytes were collected, all of which fertilised normally. Two embryos were transferred 2 days later. Her initial pregnancy test was positive and ultrasound at 7 weeks gestation confirmed an ongoing singleton intrauterine pregnancy.
DISCUSSION
Ovarian cyst formation after GnRH agonist treatment is relatively common (1-2) . In contrast, ovarian hyperstimulation is a rare event. As a complication of IVF treatment, there are only a small number of reported cases and optimal management is controversial (3) (4) (5) . The pathogenesis of ovarian hyperstimulation secondary to GnRH agonist administration is not known, although several theories have been put forward to explain its occurrence (3) .
Ovarian hyperstimulation has occurred with both early follicular and mid-luteal administration of the agonist (3) (4) (5) 7, 8) . Luteal phase administration of the GnRH agonist, as opposed to follicular phase administration, is not associated with an initial transient stimulation of the ovaries and this would theoretically be expected to reduce the risk of hyperstimulation. Ovarian hyperstimulation has been reported with different formulations of the GnRH agonist. However, it has occurred most frequently after the use of leuprolide acetate or triptorelin as intramuscular depot or short-acting subcutaneous preparations. Hyperstimulation after intranasal administration of the agonist has previously been documented in a single case. Khalaf et al. (5) reported this complication in a patient with polycystic ovaries who was commenced on intranasal buserelin 800 µg/day during the luteal phase of a menstrual cycle.
The management of patients has varied between case reports. In the majority of cases, there was spontaneous resolution (3, 4, 7, 8) and this was not dependent on continuing the agonist. In six reported cases, the decision to administer hCG and attempt oocyte retrieval was undertaken (Table I ). The average number of oocytes obtained was low. Embryo transfer was achieved in the majority of patients (71%), but there was no data regarding the quality of transferred embryos. There were no reported pregnancies and none of the patients developed severe OHSS following oocyte retrieval. Successful fertilisation after intracytoplasmic sperm injection was reported in a single case (5) .
It has been suggested that in low responders who present with multifollicular development following GnRH agonist treatment, hCG administration and oocyte retrieval may be an alternative to cycle cancellation (3). However, ovarian cyst formation following GnRH agonist administration may be associated with suboptimal response to gonadotropins and a low pregnancy rate (9) . Moreover, no pregnancy has resulted from this management strategy, although the number of reported cases is small. The potential risk of developing OHSS must be considered and discussed with the patient. Recurrence of ovarian hyperstimulation in a subsequent cycle, using the same or a different GnRH agonist has been reported, but recurrence was not a constant phenomenon. Weissman pretreated one patient with the oral contraceptive pill, but this did not prevent recurrence (3) . It has been suggested that variability in the occurrence of hyperstimulation within an individual in response to GnRH agonists may be due to intercycle variation in the number and affinity of ovarian GnRH receptors (4) .
As available data is limited, it is difficult to formulate an optimal management plan for subsequent IVF cycles in these patients. A GnRH agonist may be administered again, but a reasonable alternative would be to use a GnRH antagonist (e.g. Cetrorelix, ASTA-Medica; Ganirelix, NV Organon). Due to the different mode of action of GnRH antagonists (competitive inhibition), there is no initial flare effect as seen with GnRH agonists. Consequently, excessive follicular recruitment and ovarian hyperstimulation is less likely to occur. Recent reports have suggested that the incidence of OHSS is significantly lower when GnRH antagonists rather than agonists are used in controlled ovarian stimulation (10) . In this case, the use of a GnRH antagonist in combination with low dose human menopausal gonadotropin (Menogon) resulted in a successful cycle. This regime is worth considering in the small number of patients who hyperstimulate after the sole administration of a GnRH agonist.
In conclusion, ovarian hyperstimulation following the sole administration of a GnRH agonist is rare and its pathogenesis is not known. The condition can recur but due to the small number of reported cases, it is not possible to determine the recurrence risk. Management options include expectant management or hCG administration with oocyte retrieval. No pregnancy has yet resulted from intervention and the risk of OHSS must be considered if active intervention is planned. Management options in future cycles include the use of a GnRH antagonist that may lower the chance of recurrence of hyperstimulation.
